CS MEDICA

The Post-IPO Raise of the Year category specifically recognizes companies that have demonstrated exceptional performance and growth following their initial public offering (IPO). CS MEDICA's inclusion in this category highlights its success in navigating the complexities of the financial markets and effectively raising capital to support its strategic initiatives. 

The nomination of this award was attributed to several critical funding scenarios that CS MEDICA faced since its IPO in September 2021. These incidents highlight the company's determination and resourcefulness in securing the necessary capital for its operations and growth.

1. February 2022, CS MEDICA faced a funding challenge but managed to secure a cash capital increase of 100,000 shares to Diaz Capital Invest AB. This direct issue was conducted at a share price of 8.5 DKK per share, a total of DKK 0,85 million, representing a Share premium of 12% compared to the market price of 7.60 DKK at that time. This decision indicated the company's commitment to attracting strategic investors to support its expansion.
2. May 2022, CS MEDICA entered into loan financing agreements with Bizcap AB, Gerhard Dal, and Råsunda Förvaltning AB, totaling DKK 6 million. This move demonstrated the company's agility in exploring different financial avenues to meet its funding requirements.
3. September 2022, In a challenging stock market environment, CS MEDICA managed to raise approximately DKK 9.9 million through the exercise of TO1 warrants. These warrants had been issued at the IPO based on an IPO share price of 7.7 DKK plus a 20% premium, equivalent to 9.3 MDKK.  The warrants were to be exercised one year after the IPO, during the period August – September 2022. In mid-July 2022 the share price was only 6,6 DKK, meaning the likelihood of achieving funding from TO1 warrants was very low.  Even so, the company successfully managed to finalize all activities in a few weeks resulting in the share price increasing up to 18.7 DKK during the TO1 period. Approximately 92% of TO1 warrants were exercised, resulting in a funding infusion of DKK 9.9 million, albeit with transaction-related costs of DKK 0.8 million deducted.
4. March 2023, CS MEDICA finalized a significant investor agreement with RongShi, securing an investment of DKK 60 million through directed share issues at a share price of DKK 28.13. This represented a substantial premium of 454% compared to the closing price of DKK 5.08 on March 24, 2023. RongShi's investment amounted to 14.76% of CS MEDICA's outstanding shares and was divided into two tranches. The first tranche was contingent upon the registration and approval of 3-5 CANNASEN CBD products by the China National Medical Products Administration. The second tranche depended on CS MEDICA reaching revenues of at least DKK 62.4 million in the 12-month period following the payment of the first tranche. Non-compliance with the second tranche's requirements would result in the issuance of new shares to RongShi.

In summary, the nomination of this award recognizes CS MEDICA's exceptional efforts and strategic decisions in navigating various funding challenges since its IPO in September 2021, demonstrating its commitment to sustained growth and success in the medical industry. Read more about the nomination here.

The award ceremony will take place on the 13th of November at the Honourable Artillery Company in London. This event promises to bring together key influencers, executives, and thought leaders from the life sciences sector, providing a platform to celebrate and showcase outstanding achievements within the industry.